Once-daily TRESIBA®:
Day-to-day stability
Duration of action – beyond 42 hours12,13
Mean glucose profile in a 42-hour clamp study
in adults with type 1 diabetes (n=66)13
Tresiba® OD 0.6 U/kg
Blood glucose level (mmol/L)
Time (hours)

- 8
- 7
- 6
- 5
- 4

- 0
- 6
- 12
- 18
- 24
- 30
- 36
- 42

VARIABILITY

PREDICTABILITY

UNIQUE MOLECULE

i

TRESIBA® offers lower day-to-day
variability in glucose-lowering effect
vs glargine U30017,18*
Slow, consistent release:
Day-to-day variability in area under
the glucose infusion rate curve (CV%)
Time (hours)
TRESIBA®
Glargine U300

- 260
- 240
- 220
- 200
- 180
- 160
- 140
- 120
- 100
- 80
- 60
- 40
- 20
- 0

- 0-2
- 2-4
- 4-6
- 6-8
- 8-10
- 10-12
- 12-14
- 14-16
- 16-18
- 18-20
- 20-22
- 22-24

1.5
2.2†
3.0†
4.6†
7.9†
12.4†
11.4†
9.7†
4.8†
3.7†
4.2†
4.3†

i

- *During two 12-day treatment periods (crossover design), patients with type 1 diabetes
  underwent a 24-hour euglycaemic glucose clamp on 3 different days. The 24-hour
  euglycaemic clamp was carried out at 5.5 mmol/L. Both Tresiba® and glargine U300
  were dosed at 0.4 U/kg once daily.17,18

CV (coefficient of variation). PD (pharmacodynamic). PK (pharmacokinetic).
* In patients with type 1 diabetes in a PK/PD study.17,18
† p<0.05.
With TRESIBA® you can help give
them daily predictability12,17,18
SIGNIFICANTLY LOWER
DAY-TO-DAY
VARIABILITY
WITH TRESIBA®
VS GLARGINE
U10012*†

i

- †Day-to-day variability in glucose-lowering effect during one dosing interval of 0–24 hours
  at steady state (AUCGIR,τ,SS) is 20% for Tresiba®.12

AUCGIR,τ,SS (area under the curve, glucose infusion rate, torque, steady state).
PD (pharmacodynamic). PK (pharmacokinetic).
* In glucose-lowering effect in patients with type 1 diabetes in a PK/PD study.
Benefit from the unique
TRESIBA® molecule12,16
Slow, consistent release:
After injection, Tresiba®
molecules bind to form chains12,13,16
Individual molecules are then
slowly and consistently released
into the circulation12,13,16
Play
molecule animation
42-hour euglycaemic clamp on day 8 under steady-state conditions with once-daily dosing.13
OD (once-daily).